Release Date: 21-Jul-2024
Fruquintinib, developed by HUTCHMED, is a highly selective oral inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3. This potent small molecule has shown promise in treating various solid tumors.
The drug achieved its first major milestone in September 2018 with marketing approval in China, where it is co-marketed as Elunate by HUTCHMED and Eli Lilly. Its inclusion in China’s National Reimbursement Drug List in January 2020 further expanded its accessibility. The approval was based on the successful FRESCO study, a pivotal Phase III trial in metastatic colorectal cancer patients. By mid-2023, fruquintinib had benefited over 80,000 colorectal cancer patients in China.
Fruquintinib’s global expansion continued with FDA approval in November 2023 for previously treated metastatic colorectal cancer, marketed as Fruzaqla by HUTCHMED’s partner Takeda. This approval marks a significant step in fruquintinib’s journey to become a global treatment option for cancer patients.
For More Information on Drug Trials in China Contact